Kaftrio: Real World Data Failed To Impress European Reviewers
EU Indication For Vertex's Triple CF Combination Is Narrower Than In US
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
